<DOC>
	<DOCNO>NCT01703533</DOCNO>
	<brief_summary>The purpose study determine whether NNZ-2566 safe well tolerate treatment Rett Syndrome adolescent adult female .</brief_summary>
	<brief_title>A Safety Study NNZ-2566 Patients With Rett Syndrome</brief_title>
	<detailed_description>Rett Syndrome developmental disorder primarily exclusively affect female . The disorder characterize apparent normal development early infancy ( 6-18 month ) , follow period regression onset systemic neurological sign . The CNS symptom Rett Syndrome include learn disability , autism epilepsy severe highly debilitate . Affected individual also show sign autonomic dysfunction , reflect cardiovascular respiratory abnormality . There currently effective treatment Rett Syndrome . This study investigate safety tolerability treatment oral administration NNZ-2566 35 mg/kg 70 mg/kg BID adolescent adult female Rett Syndrome . The study also also investigate measure efficacy treatment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Rett Syndrome</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Diagnosis Rett Syndrome proven mutation MeCP2 gene Age 16 45 year Severity rating 10 36 ( Rett Syndrome Natural History/Clinical Severity Scale ) Concomitant medication must stable &gt; 4 week prior enrollment . The following concomitant medication permit : anticonvulsant liver induce effect ; betablockers ; medication treatment gastroesophageal reflux disease ( GERD ) ; medication treatment chronic respiratory condition asthma ; medication treatment anxiety , depression psychosis , hormonal contraceptive . Melatonin difficulty sleep onset . Ability swallow study medication provide liquid solution , via gastrostomy tube No detectable abnormality EEG screening period Actively undergoing regression QTcF exclusion ( follow ) : baseline/screening QT/QTcF interval 450 msec ; history risk factor torsade de pointes ( e.g . heart failure , hypokalemia ( serum potassium screen &lt; 3.0 mmol/L ) family history long QT syndrome ; QT/QTcF prolongation previously currently control medication Current treatment insulin Hgb A1C value outside normal reference range screen Current past treatment IGF1 Current past treatment growth hormone Current treatment NmethylDaspartate ( NMDA ) antagonists Current plan use nonmedication base interventional therapy period study ( define 46 week screen period follow 4 week dose 2 week followup period ) Current clinically significant cardiovascular , renal , hepatic respiratory disease Gastrointestinal disease may interfere absorption , distribution , metabolism excretion study medication History , current cerebrovascular disease brain trauma History , current significant endocrine disorder e.g . hypo hyperthyroidism diabetes mellitus History , current malignancy Clinically significant abnormality safety laboratory test , vital sign ECG , measure screen baseline Confirmed pregnancy Significant hearing and/or visual impairment may affect ability complete test procedure Enrollment another clinical trial within previous 30 day Previously randomize clinical trial Allergy strawberry</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Autism</keyword>
	<keyword>Rett 's Syndrome</keyword>
	<keyword>Rett Disorder</keyword>
	<keyword>Rett 's Disorder</keyword>
	<keyword>Ataxia</keyword>
</DOC>